ID
39965
Beskrivning
Study ID: 110852 Clinical Study ID: 110852 Study Title: MD7110852, A Phase 2b Dose-Ranging Study of Pazopanib Eye Drops versus Ranibizumab Intravitreal Injections for the Treatment of Neovascular Age-Related Macular Degeneration Patient Level Data: Study Listed on ClinicalStudyDataRequest.com Clinicaltrials.gov Identifier: NCT01134055 Sponsor: GlaxoSmithKline Phase: Phase 2 Study Recruitment Status: Completed Generic Name: pazopanib eye drops, ranibizumab intravitreal injection, placebo Trade Name: pazopanib, ranibizumab Study Indication: Macular Degeneration
Nyckelord
Versioner (1)
- 2020-03-06 2020-03-06 -
Rättsinnehavare
GlaxoSmithKline
Uppladdad den
6 mars 2020
DOI
För en begäran logga in.
Licens
Creative Commons BY-NC 4.0
Modellkommentarer :
Här kan du kommentera modellen. Med hjälp av pratbubblor i Item-grupperna och Item kan du lägga in specifika kommentarer.
Itemgroup-kommentar för :
Item-kommentar för :
Du måste vara inloggad för att kunna ladda ner formulär. Var vänlig logga in eller registrera dig utan kostnad.
Pazopanib Eye Drops versus Ranibizumab Intravitreal Injections for the Treatment of Neovascular Age-Related Macular Degeneration NCT01134055
Week 8; 12; 16; 20; 32; 36; 40; 44; 48 - ETDRS Refraction; ETDRS Visual Acuity; Intraocular Pressure Exam; Ocular Status; External Ocular Exam; Eye Lid and Lash Exam
Similar models
Week 8; 12; 16; 20; 32; 36; 40; 44; 48 - ETDRS Refraction; ETDRS Visual Acuity; Intraocular Pressure Exam; Ocular Status; External Ocular Exam; Eye Lid and Lash Exam
C2985720 (UMLS CUI [1,2])
C0229089 (UMLS CUI [1,2])
C0229089 (UMLS CUI [1,2])
C0229089 (UMLS CUI [1,2])
C0229090 (UMLS CUI [1,2])
C0229090 (UMLS CUI [1,2])
C0229090 (UMLS CUI [1,2])
C1264639 (UMLS CUI [1,2])
C0600091 (UMLS CUI [1,2])
C2646699 (UMLS CUI [1,3])
C0229089 (UMLS CUI [1,2])
C0444686 (UMLS CUI [1,3])